This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nominations Pursuant To Advance Notice Policy

About Todd Axelrod's nominees

The nominees proposed by Mr. Todd Axelrod are the following:

Me Pierre Dozois, 66, from Montréal, Quebec, Canada, is a senior partner of BCF since 1977 and has completed his studies at the Faculty of Law of Université de Montréal and Harvard Business School. His current practice is mainly focused on mergers and acquisitions and on public and private financing. He has been a member of board of directors of corporations and non-profit charitable organizations. He has been a director and president of Club St-Denis de Montréal and of Fondation de l'Hôpital Notre-Dame de Montréal. He is now a director and member of the Executive Committee of Fondation du Centre hospitalier universitaire de Montréal (CHUM).

Mr. Paul Guay, 64, from Beaconsfield, Quebec, Canada, is a certified accountant. He has been Vice-President, Finances and Administration of Groupe BMR inc. and of Produits de Piscines Vogue inc. He has performed many mandates in recovery, reorganization, financing and diagnostic of companies in many sectors, generally for institutional investors. His experience with publicly traded companies was acquired while he was acting as interim CFO of Ranaz Corporation, a TSX venture company. He currently is a consultant in finance and reorganization. Mr. Guay also disclosed having acted as chief financial officer of Accessoires de piscine Compétition Inc. from January 2008 to August 2008. This company declared bankruptcy in December 2009. From January 2011 until April 2013, he has acted as chief financial officer of Mechtronix Systems Inc. Mechtronix and affiliated companies declared bankruptcy between June and October 2012.

Mr. Hans Mäder, 66, from Valleyfield, Quebec, Canada, had been president and chief executive officer of Ambrilia Biopharma from March 2006 to April 2007. He has acted as chairman of the board, president and chief executive officer of Procyon Biopharma from 1999 until March 2006. He was responsible for the listing of Procyon's shares on the Toronto Stock Exchange and has negotiated license agreements with pharmaceutical partners. He has been president and chief executive officer for Novartis Pharmaceuticals Inc. Canada and has held various functions at Sandoz Canada Inc. and Sandoz Pharmaceuticals inc. in the United States. He currently acts as consultant for North American biotech and pharma companies.

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage TM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA ® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, please visit

Forward‐looking statements

This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward‐looking statements. For instance, the forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PROGENSA® PCA3, are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs